In Brief This Week: Theradiag; Sigma-Aldrich; Transgenomic; Hologic; CommonMind Consortium; Benaroya Research Institute | GenomeWeb

NEW YORK (GenomeWeb News) – Theradiag said today that it has received the CE Mark for two new biotherapy monitoring kits: tocilizumab and rituximab. Tocilizumab is an immunosuppressive drug used to treat rheumatoid arthritis and juvenile idiopathic arthritis, while rituximab is prescribed for treatment of leukemia and lymphoma. The Theradiag kits are sold under the Lisa Tracker brand name.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.